• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Handheld Allergy Relief Device Maker Raises $8M in Seed Funding

Share:

July 30, 2019

Tivic Health’s ClearUP Sinus Pain Relief

Tivic Health Systems, maker of a commercial sinus pain relief device, announced yesterday that it has raised $8 million in seed funding. Sand Hill Angels, Astia Angels, Golden Seeds, HBS Angels, Sierra Angels, Lateral Capital, Skylight Investments, an unnamed physician network and individual investors each backed the company through a series of smaller investments, the most recent of which the startup said closed last week.

WHAT THEY DO
Tivic’s primary product, the ClearUP Sinus Pain Relief device, is a non-invasive, over-the-counter treatment for hay fever sinus pains. Upon pressing a single button when holding the product up to the cheek, nose or brow, it delivers a low electrical current that stimulates nerves below the skin and provides relief. The ClearUP device received 510(k) clearance in January and, according to the company, is slated to launch commercially in mid-September at $149.

WHAT IT’S FOR
Tivic said in its funding announcement that the new money will fuel a marketing push for the ClearUP device’s upcoming launch.

MARKET SNAPSHOT
Tivic’s product stands out as a device that directly treats sinus pain, but others have built tools that can help those susceptible avoid conditions in which their allergies may be aggravated — for instance, Propeller Health’s respiratory health forecasting services. Similarly, direct-to-consumer telemedicine consultation service PlushCare also offers consultations with allergy specialists that can help these users manage their allergies.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

ON THE RECORD
“Bioelectronics is a high growth industry and is expanding rapidly. Until recently, bioelectronic medicine has been accessible primarily through implantable devices,” Jennifer Ernst, CEO and co-founder of Tivic Health, said in a statement. “Today more companies are developing non-invasive solutions. ClearUP harnesses the power of neuromodulation into a consumer-friendly, non-invasive treatment that will help the more than 40 million Americans suffering from the frustrating sinus pain symptom of allergies.”

Date: July 30, 2019

Source: <span style=”color: #000000;”><a style=”color: #000000;” href=”https://tivichealth.com/articles/handheld-allergy-relief-device-maker-raises-8m-seed-funding/” target=”_blank” rel=”noopener noreferrer”>Tivic Health</a></span>

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Moderna to Acquire OriCiro GenomicsModerna to Acquire OriCiro Genomics
  • Telix Accelerates Artificial Intelligence (AI) Development Program with Acquisition of DedicaidTelix Accelerates Artificial Intelligence (AI) Development Program with Acquisition of Dedicaid
  • Todos Medical Enters Into Binding Agreement to Acquire all 3CL Protease Biology-Related Assets and Intellectual Property from NLC PharmaTodos Medical Enters Into Binding Agreement to Acquire all 3CL Protease Biology-Related Assets and Intellectual Property from NLC Pharma
  • The Growing Emergence of Robots in Healthcare: Key Opportunities & BenefitsThe Growing Emergence of Robots in Healthcare: Key Opportunities & Benefits
  • Study: AI-Powered Solution Achieves High Accuracy for Detecting COVID-19 on CTStudy: AI-Powered Solution Achieves High Accuracy for Detecting COVID-19 on CT
  • Jazz Pharmaceuticals Acquires Pre-clinical Pan-RAF Inhibitor Program from Redx PharmaJazz Pharmaceuticals Acquires Pre-clinical Pan-RAF Inhibitor Program from Redx Pharma
  • Leading Proxy Advisory Firms Glass Lewis and ISS Recommend Cellular Biomedicine Group Stockholders Vote FOR Proposed MergerLeading Proxy Advisory Firms Glass Lewis and ISS Recommend Cellular Biomedicine Group Stockholders Vote FOR Proposed Merger
  • AI-powered risk prediction platform KenSci secures $22MAI-powered risk prediction platform KenSci secures $22M

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications